Homehealthcare News

    CNBC-TV18 Exclusive: Russia's Sputnik V vaccine to be rolled out in April-May

    healthcare | IST

    CNBC-TV18 Exclusive: Russia's Sputnik V vaccine to be rolled out in April-May

    Mini

    RDIF currently has five domestic partners but plans to add more in the future, Dmitriev said, to ramp up the production in the coming months. RDIF has reached agreements with Dr Reddy's Laboratories, Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma, and Virchow Biotech.

    The roll-out of Russia's COVID-19 vaccine, Sputnik V, will begin at the end of April or early May. The vaccine will be priced lower for India, Russia's RDIF is working out solutions with the government, its CEO Kirill Dmitriev, told CNBC-TV18 in an interview.
    India became the 60th country to approve emergency use authorisation (EUA) of Sputnik V on Monday. RDIF is looking to produce over 850 million doses per year, making India the main production hub for the vaccine.
    Dmitriev added that the initial rollout will be met by imports, domestic manufacturing, and fill and finish. The vaccines exported from India will cost higher in Indian markets, he said. Exports demand have come largely from Latin America, Central Europe, UK, Africa, South East Asia.
    The vaccine, meant for people aged 18 and above, can be stored at 2-8 degrees for two months.
    RDIF currently has five domestic partners but plans to add more in the future, Dmitriev said, to ramp up the production in the coming months. RDIF has reached agreements with Dr Reddy's Laboratories, Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma, and Virchow Biotech.
    The efficacy of Sputnik V vaccine is 91.6 percent, as confirmed by the data published in the leading medical journal, Lancet. Here is everything you need to know about Sputnik V.
    Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
    next story

      Most Read

      Market Movers

      View All
      CompanyPriceChng%Chng